Romiplostim Articles
More news briefs from ASH meeting
14 December 2011
Amgen buys Bergamo for $215 million, thus establishing commercial operations in Brazil
11 April 2011
UK’s NICE backs Merck & Co’s Simponi and Amgen’s Nplate
18 March 2011
Amgen's Nplate reduces number of splenectomies
8 June 2009
Amgen gets EC appro for Nplate in ITC
16 February 2009
FDA 2008 NCE appros exceed expectations
12 January 2009
ASH hears strong data on Novartis
22 December 2008
74% of ITP patients achieve platelet response on Nplate
15 December 2008
CHMP gives nod to four new drugs at meeting
1 December 2008
FDA approves Amgen
1 September 2008
Expected US approval of Amgen
28 July 2008
Long-term use potential for romiplostim
23 June 2008
FDA expert panel recommends Amgen ITP drug
17 March 2008
Amgen's romiplostim meets Phase III endpoints in ITP
17 December 2007
Amgen files romiplostim NDA with US FDA
29 October 2007
Showing 1-20 of 20 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
